Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX) and the PAM50 Breast Cancer Intrinsic Classifier in Early-Stage Estrogen Receptor–Positive Breast Cancer

The Oncologist, 04/25/2012

The findings suggest that there is good agreement between the two assays for high and low prognostic risk assignment but PAM50 assigns more patients to the low risk category. About half of the intermediate Recurrence Score (RS) group was reclassified as luminal A by PAM50.

Print Article Summary Cat 2 CME Report